- Home
- BP vs GSK Comparison
BP vs GSK Comparison
Compare BP & GSK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BP | GSK |
|---|---|---|
| Founded | 1889 | 1715 |
| Country | United Kingdom | United Kingdom |
| Employees | N/A | N/A |
| Industry | Integrated oil Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 81.9B | 95.3B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | BP | GSK |
|---|---|---|
| Price | $35.90 | $48.12 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 1 |
| Target Price | ★ $39.87 | N/A |
| AVG Volume (30 Days) | ★ 6.8M | 4.2M |
| Earning Date | 11-04-2025 | 10-29-2025 |
| Dividend Yield | ★ 5.42% | 3.42% |
| EPS Growth | N/A | ★ 118.57 |
| EPS | 0.09 | ★ 1.79 |
| Revenue | ★ $185,934,000,000.00 | $43,237,357,842.00 |
| Revenue This Year | $0.76 | $6.56 |
| Revenue Next Year | N/A | $5.13 |
| P/E Ratio | $378.48 | ★ $27.14 |
| Revenue Growth | N/A | ★ 2.73 |
| 52 Week Low | $25.23 | $31.72 |
| 52 Week High | $37.64 | $49.31 |
Technical Indicators
Market Signals| Indicator | BP | GSK |
|---|---|---|
| Relative Strength Index (RSI) | 49.06 | 56.81 |
| Support Level | $35.71 | $48.01 |
| Resistance Level | $37.44 | $49.31 |
| Average True Range (ATR) | 0.49 | 0.61 |
| MACD | -0.10 | -0.06 |
| Stochastic Oscillator | 24.21 | 63.77 |
Price Performance
Historical ComparisonAbout BP BP p.l.c.
BP is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2024, it produced 1.2 million barrels of liquids and 6.9 billion cubic feet of natural gas per day. At the end of 2024, reserves stood at 6.2 billion barrels of oil equivalent, 59% of which are liquids. The company operates refineries with a capacity of 1.6 million barrels of oil per day.
About GSK GSK plc (Each representing two)
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.